Aptiom to acquire all outstanding shares of common stock of Sepracor
November 22, 2015
Integrated Diagnostics will have access to Dr. Hood's groundbreaking research at ISB investigating protein blood markers that can report on the physiological state of the body's 50 major organs. His research uses genomic and proteomic techniques to identify blood proteins that are only synthesized in the organ of interest and then identifies subtle changes that result from disease or treatment. By monitoring concentrations of these proteins in the blood, disruptions in healthy function can be detected and traced back to the diseased organ. This work is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules.
Through its research collaborations, Integrated Diagnostics possesses proprietary data on organ-specific proteins across a range of human organs. These protein panels are applicable to many diagnostic modalities including early detection of disease, stratification of disease types, and monitoring disease progression and recurrence. The company's technology is applicable to a broad scope of diseases, including cancer, diabetes and Alzheimer's disease.
"Integrated Diagnostic's research enabling technologies will allow us to cut in half the standard development times for diagnostics," said Dr. Hood. "In addition, the company's technologies will ultimately permit the rapid analysis of blood biomarkers from just a fraction of a droplet of blood, at a cost of less than one dollar per protein measured."
SOURCE: Integrated Diagnostics